Akebia Therapeutics, Inc. (AKBA)

Trade AKBA now with
11/12/2019 8:01:16 AM Akebia Therapeutics Q3 Loss Per Share $0.46, Same As Last Year
8/5/2019 8:08:14 AM Akebia Therapeutics Announces Settlement Of Auryxia Patent Litigation With Par
7/23/2019 4:14:36 AM Akebia Therapeutics Announces Submission Of Vadadustat NDA In Japan
7/10/2019 8:05:38 AM Akebia Therapeutics Announces Collaboration Partner’s Positive Top-line Results Of Phase 3 Clinical Study Of Riona
4/9/2019 1:04:39 AM Vifor Pharma And Akebia Therapeutics Announce Expansion Of License Agreement
12/13/2018 7:07:36 AM Akebia Therapeutics And Keryx Biopharmaceuticals Complete Merger
12/11/2018 12:07:54 PM Akebia Therapeutics Shareholders Approve Merger With Keryx
11/30/2018 8:56:04 AM Glass Lewis Joins ISS In Recommending Akebia Shareholders Vote For” Proposed Merger With Keryx
11/29/2018 7:04:57 AM ISS Recommends Akebia Shareholders Vote For Proposed Merger With Keryx
11/29/2018 7:03:34 AM ISS Recommends That Keryx Biopharmaceuticals Stockholders Vote “FOR” The Proposed Merger With Akebia Therapeutics
8/28/2018 4:13:32 PM Akebia Therapeutics Appoints Cynthia Smith To Its Board Of Directors
6/28/2018 7:09:39 AM Akebia Therapeutics, Trading Expected To Resume At 7:30 AM ET
6/28/2018 7:07:24 AM Akebia Therapeutics, Keryx Biopharmaceuticals To Combine In An All-stock Merger
6/28/2018 7:01:16 AM Akebia Therapeutics, Trading Halted Pending News
3/23/2018 8:02:12 AM Akebia Therapeutics Announces Pricing Of Public Offering Of 8.5 Mln Shares At $10.50/Shr
3/22/2018 4:27:49 PM Akebia Therapeutics Announces Proposed Public Offering Of Common Stock